ArticleMikrochimica acta2026
Precise and simultaneous SERS detection of sertraline and serotonin on large-scale sub-20 nm plasmonic gold nanocone arrays.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A highly sensitive and reproducible SERS platform for sertraline and serotonin detection is presented using large-scale, cost-effective, and facile fabrication of sub-20 nm nanogaps in plasmonic gold nanocone (AuNC) arrays. They , ensure a high density of uniform electromagnetic enhancement sites, giving the platform "hot-spot" consistency. The sertraline limit of detection (LOD) of 88 ng/mL is two orders of magnitude lower than clinical values, representing the lowest SERS-based LOD for sertraline reported to date. The LOD for serotonin, 27 ng/mL, is lower than its blood levels, even in depression. Moreover, simultaneous, parallel detection of both analytes within artificial cerebrospinal fluid (aCSF) mimicking physiological composition was achieved with no sample pretreatment, highlighting the platform's high selectivity. Our method shows great potential for complex antidepressant therapeutic monitoring in clinical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.